clinical trial · NCT06078592
Comparison of Efficacy and Ocular Surface Assessment Between BRIDIN-plus and Combigan in Glaucoma or Ocular Hypertensive
CHA University·phase4·completed·n = 60
GlaucomaOcular HypertensiveBRIDIN-plus Eye dropsCombigan Eye drops
brief summary
Comparison of Efficacy and Ocular Surface Disease Assessment between BRIDIN-plus Eye drops and Combigan Eye drops in Glaucoma or Ocular Hypertensive Patients : Phase 4, Parallel Group Design, Investigator-blind, Active-control, Randomized, Multi-center Trial
started
Oct 8, 2021
primary completion
Dec 23, 2022
completion
Dec 23, 2022
last updated
Mar 26, 2025
detailed description
The purpose of this clinical trial is to prove lower negative effects on ocular surface disease and higher patient compliance of a single-use formula BRIDIN-PLUS® eye drops group, comparing to a multi-use formula COMBIGAN® eye drops after 12 weeks of administration to glaucoma or ocular hypertensive patients.
official title
Comparison of Efficacy and Ocular Surface Disease Assessment Between BRIDIN- PLUS® Eye Drops and COMBIGAN® Eye Drops in Glaucoma or Ocular Hypertensive Patients
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol